key: cord-1051234-xkn3wmhj authors: Smoke, Steven M.; Leach, Henry; Leonida, Nicole; Raja, Karan; Shah, Monica; Patel, Vishal; Patel, Gargi; Daniel, Nicole M.; Gerges, Jessica; Patel, Akshar title: Medication safety in a pandemic: A multicentre point prevalence study of QTc monitoring of hydroxychloroquine for COVID‐19 date: 2021-05-06 journal: J Clin Pharm Ther DOI: 10.1111/jcpt.13429 sha: 7c51d4ba06a5927e4869c412fb8dea80d52d4eff doc_id: 1051234 cord_uid: xkn3wmhj WHAT IS KNOWN AND OBJECTIVE: A pandemic can strain all aspects of the healthcare system, including the ability to monitor the safety of medication use. Reviewing the adequacy of medication safety practices during the COVID‐19 pandemic is critical to informing responses to future pandemics. The purpose of this study was to evaluate medication safety practices at a height of both COVID‐19 cases and hydroxychloroquine use. METHODS: This was a multicentre observational point prevalence study. Adult inpatients receiving hydroxychloroquine for COVID‐19 between March 22 and 28, 2020 were included. The primary outcome was the percentage of patients receiving appropriate QTc monitoring. Secondary outcomes included QTc prolongation, early discontinuation of hydroxychloroquine and ventricular arrhythmias. RESULTS AND DISCUSSION: A total of 59% (167/284) of patients treated with hydroxychloroquine received appropriate QTc monitoring. QTc prolongation occurred in 25%. Hydroxychloroquine was prematurely discontinued in 1.4% of patients, all due to QTc prolongation. Ventricular arrhythmia occurred in 1.1%. WHAT IS NEW AND CONCLUSION: Medication safety practices were suboptimal with regard to hydroxychloroquine monitoring at the height of the COVID‐19 pandemic. Preparation for future pandemics should devote considerable attention to medication safety. created an environment ripe for widespread use of unproven medications. One of the earliest of these was the use of hydroxychloroquine with or without azithromycin. Initially, evidence supporting chloroquine-based management of COVID-19 infection was drawn from in vitro studies. 2 The first clinical study by Gautret et al. popularized not only hydroxychloroquine but also combination therapy with azithromycin. 3 Although the studies published were methodologically flawed, 4 these findings had amonumental impact on COVID-19 treatment worldwide. These publications, in addition to the U.S. presidential press conference highlighting their results, were followed by dramatic increases in internet searches 5 and prescription fills 6 for hydroxychloroquine. Subsequent, higher quality studies have consistently found no benefit with the use of hydroxychloroquine with or without azithromycin for the treatment of COVID-19 infection. [7] [8] [9] An advantage of repurposing medications during a pandemic is the potentially well-known safety profiles of these therapies. Hydroxychloroquine and azithromycin are generally well tolerated; however, both drugs inhibit the delayed rectifier potassium current, delaying cardiac repolarization. 10 Both drugs have been linked to QTc prolongation which is associated with Torsades de pointes (TdP), other ventricular arrhythmias and sudden cardiac death. 11 Several patient-specific factors can increase the risk for QTc prolongation including age, gender, comorbidities and electrolyte abnormalities. Both hydroxychloroquine and azithromycin are considered nonantiarrhythmic drugs with known risk for TdP. 12 When initiating these drugs in patients with underlying risk factors for TdP, the American Heart Association recommends baseline and subsequent electrocardiogram (ECG) monitoring to minimize the risk of QTc prolongation and arrhythmia. 11 Appraising practices from this pandemic are key to identifying opportunities to improve responses to future pandemics. With overwhelming numbers of cases and strained resources, providers may not have approached medication safety with the same diligence as they would have outside of a pandemic. The purpose of this study was to evaluate medication safety practices at a height of both COVID-19 cases and hydroxychloroquine use. This was a retrospective point prevalence study conducted at 4 hospitals within a New Jersey health system. These hospitals range in bed size from 332 to 597, and include both teaching and non-teaching community hospitals. Inpatients who tested positive for SARS-CoV-2 by nasopharyngeal PCR between 22 March 2020 and 28 March 2020 and were treated with hydroxychloroquine for greater than 2 days were included in the study. Patients receiving hydroxychloroquine for an alternative indication or not requiring QTc monitoring (due to a lack of risk factors for QTc prolongation) were excluded. The presence of risk factors included in the Tisdale Risk Score was used to determine the requirement for QTc monitoring. This particular date range was chosen due to a peak of both COVID-19 cases in the area and attention on hydroxychloroquine from both the scientific and public communities. 5 During this time period, health system guidance at the study hospitals on treatment of COVID-19 recommended hydroxychloroquine 400 mg every 12 h × 2 doses on day 1, followed by 400 mg once daily on days 2-5 for all patients who did not have contraindications. QTc monitoring was recommended but no particular guidance on monitoring frequency was provided. Decisions regarding treatment and monitoring were subject to the discretion of the care team. The primary outcome of this study was to determine the percentage of patients who received appropriate QTc monitoring among those in which it was indicated. Appropriate monitoring was defined as a baseline ECG prior to treatment and either a follow-up ECG within 48 h of treatment initiation or continuous cardiac monitoring during therapy. 11 Tisdale risk scores, which predict the risk of QTc prolongation, were calculated for each patient. 12 The Tisdale Risk Score calculation was modified to expand the list of drugs considered to be QTc-prolonging, consistent with CredibleMeds. This included the addition of hydroxychloroquine and azithromycin among other medications. 13 Secondary outcomes included QTc prolongation (defined as any QTc ≥500 ms or a ≥60 ms increase in QTc), discontinuation of hydroxychloroquine due to an adverse drug event, and ventricular arrhythmias. Causality was assessed using the modi- A total of 353 patients tested positive for SARS-CoV-2 and were hospitalized for greater than 48 h during the study period. In this study, there was widespread use of medications ultimately proven to be ineffective for the treatment of COVID-19 infection. Therefore, creative monitoring strategies may be particularly useful. Giudicessi et al proposed smartphone-enabled mobile ECG monitoring to limit personnel exposure and conserve PPE. 20 The aforementioned study conducted by Saleh et al, which had uniform compliance with QTc monitoring, described the use of mobile cardiac outpatient telemetry patches to monitor QTc in patients on non-telemetry units. 17 More than half of their cohort was monitored via this method. This high compliance likely reflects a rigorous health system-wide monitoring plan that was flexible enough to maintain feasibility during the pandemic surge. Such planning is key to maintaining high quality medication monitoring during a pandemic. QTc prolongation was fairly common in this cohort, occurring in 25% of patients with adequate monitoring. Other studies have found rates ranging from 5 to 33%. [15] [16] [17] [21] [22] [23] Notably, QTc intervals in our study were automatically calculated and not manually adjudicated which may impact the accuracy of these results. Adverse outcomes were rare which is consistent with previous studies. Yet, adverse event identification may have been hindered by suboptimal monitoring or incomplete clinician documentation during the pandemic. Therefore, these safety outcome rates should be interpreted with caution. Reflecting on the COVID-19 pandemic is critical to identifying enduring lessons for future pandemics. It is impossible to know what repurposed drugs will show promise as treatments for the next pan- demic. Yet, their toxicities may be well known. Seymour et al call for clinicians to practice sensible medicine amidst the COVID-19 pandemic. 24 They offer several strategies, including elevating usual care and focusing on practices with known patient benefits. In this study, there was widespread use of unproven medications and inadequate medication monitoring at the height of the COVID-19 pandemic. Adverse outcomes were rare, although this is difficult to know with certainty due to limitations in monitoring. Preparation for the next pandemic must include an emphasis on practices known to improve patient outcomes, including a significant attention to medication safety. Not applicable. The authors would like to acknowledge Jennifer Sternbach, PharmD for her support of this work. The authors have no relevant conflicts of interest to disclose. https://orcid.org/0000-0003-4847-3432 Henry Leach https://orcid.org/0000-0003-1142-9868 Vishal Patel https://orcid.org/0000-0002-0886-5063 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial Statement of the International Society of Antimicrobial Chemotherapy (ISAC) posted on its website. 2020 A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19 Prescription fill patterns for commonly used drugs during the COVID-19 pandemic in the United States Effect of hydroxychloroquine in hospitalized patients with Covid-19 Hydroxychloroquine in nonhospitalized adults with early COVID-19: A randomized trial Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 Mechanistic insights into ventricular arrhythmogenesis of hydroxychloroquine and azithromycin for the treatment of Update to practice standards for electrocardiographic monitoring in hospital settings: a scientific statement from the American Heart Association Development and validation of a risk score to predict QT interval prolongation in hospitalized patients The Use of the WHO-UMC System for Standardized Case Causality Assessment. The Uppsala Monitoring Centre Risk of qt interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019(COVID-19) Experience with hydroxychloroquine and azithromycin in the coronavirus disease 2019 pandemic: implications for qt interval monitoring Effect of chloroquine, hydroxychloroquine, and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection Implementation of a QTc-interval monitoring protocol by pharmacists to decrease cardiac risk in at-risk patients in an acute care inpatient psychiatric facility Impact of pharmacist intervention on electrocardiogram monitoring of pediatric patients on multiple QTc interval-prolonging medications Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19) QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin Assessment of QT intervals in a case series of patients with Coronavirus disease 2019 (COVID19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit Incidence and determinants of QT interval prolongation in COVID-19 patients treated with hydroxychloroquine and azithromycin Sensible medicinebalancing intervention and inaction during the COVID-19 pandemic Medication safety in a pandemic: A multicentre point prevalence study of QTc monitoring of hydroxychloroquine for COVID-19